| 0.9377 0.016 (1.75%) | 01-21 10:36 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.57  |
1-year : | 1.92 |
| Resists | First : | 1.34 |
Second : | 1.64 |
| Pivot price | 1.12 |
|||
| Supports | First : | 0.86 |
Second : | 0.71 |
| MAs | MA(5) : | 1.05 |
MA(20) : | 1.13 |
| MA(100) : | 0.9  |
MA(250) : | 0.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.2 |
D(3) : | 35 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 3.7 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CYPH ] has closed below the lower bollinger band by 11.0%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CYPH ] is to continue within current trading range. It is unclear right now based on current values. 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.1 | 1.1 - 1.11 |
| Low: | 1 - 1.01 | 1.01 - 1.02 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Sat, 10 Jan 2026
Cypherpunk Technologies Expands Zcash Holdings by $18 Million - MSN
Wed, 31 Dec 2025
Cypherpunk Technologies restructures CoinXit equity compensation agreement - The Globe and Mail
Wed, 31 Dec 2025
CYPH Stock: Insights on Current Trends - StocksToTrade
Tue, 30 Dec 2025
Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC - PR Newswire
Mon, 29 Dec 2025
Rapid Rise of CYPH: What’s Fueling It? - timothysykes.com
Fri, 19 Dec 2025
CYPH’s Stock Movement: What’s Going On? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 22.4 (%) |
| Held by Institutions | 28.8 (%) |
| Shares Short | 5,060 (K) |
| Shares Short P.Month | 3,480 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -77.8 % |
| Return on Equity (ttm) | -196.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.76 |
| PEG Ratio | 0 |
| Price to Book value | 15.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|